NCT03633487

Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet

A Phase I, Open-label, Single-dose, Single Period Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Bi-layer Tablet in Normal Healthy Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Reckitt Benckiser LLC · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Characterize and assess PK of guaifenesin in Mucinex® 1200 mg ER Bi-Layer Tablet

Detailed description

A Phase I, Open-Label, Single-Dose, Single Period Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Bi-Layer Tablet in Normal Healthy Subjects

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	Mucinex®	Mucinex® 1200 mg ER Bi-Layer tablet

Timeline

• Start date: 2011-10-11
• Primary completion: 2011-10-15
• Completion: 2011-10-15
• First posted: 2018-08-16
• Last updated: 2019-02-28
• Results posted: 2019-02-28

Regulatory

• FDA-regulated drug study